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E-mail: fraldi@tigem.itLysosomal storage diseases (LSDs) are inherited disorders
caused by lysosomal deﬁciencies and characterized by dysfunc-
tion of the autophagy-lysosomal pathway (ALP) often associ-
ated with neurodegeneration. No cure is currently available
to treat neuropathology in LSDs. By studying a mouse model
of mucopolysaccharidosis (MPS) type IIIA, one of the most
common and severe forms of LSDs, we found that multiple
amyloid proteins including a-synuclein, prion protein (PrP),
Tau, and amyloid b progressively aggregate in the brain. The
amyloid deposits mostly build up in neuronal cell bodies
concomitantly with neurodegeneration. Treating MPS-IIIA
mice with CLR01, a “molecular tweezer” that acts as a broad-
spectrum inhibitor of amyloid protein self-assembly reduced
lysosomal enlargement and re-activates autophagy ﬂux. Resto-
ration of the ALP was associated with reduced neuroinﬂamma-
tion and amelioration of memory deﬁcits. Together, these data
provide evidence that brain deposition of amyloid proteins
plays a gain of neurotoxic function in a severe LSD by affecting
the ALP and identify CLR01 as new potent drug candidate for
MPS-IIIA and likely for other LSDs.
INTRODUCTION
Lysosomal storage diseases (LSDs) are a group of metabolic diseases
caused by inherited defects in lysosomal or non-lysosomal proteins
leading to lysosomal storage and global dysfunction often associated
with neurodegeneration.1–3 Accumulating evidence has established
that in LSDs, lysosomal dysfunction is primarily characterized by
an impairment of the autophagy-lysosomal pathway (ALP), one of
the major intracellular clearance systems.4 In particular, we have
shown that autophagy ﬂux is blocked in neurodegenerative LSDs.5
Currently there is no cure to treat neuropathology in these diseases.
In many neurodegenerative diseases including Alzheimer’s and
Parkinson’s diseases, neurotoxicity is associated with the forma-This is an open access article undetion of insoluble aggregates of amyloidogenic proteins, which,
therefore, represent therapeutic targets for these neurological
conditions.6 Accumulation of a-synuclein, a known amyloidogenic
protein, has been shown to trigger neurotoxicity through aggrega-
tion-dependent mechanisms in Gaucher disease, a severe LSD
with neurological involvement.7 Brain deposition of amyloido-
genic proteins has been reported to occur mostly as an epiphe-
nomenon in other neurodegenerative LSDs, including mucopolysac-
charidosis (MPS) type IIIA, type IIIB, sialidosis, and Krabbe
disease.8–11
Recently, we have demonstrated that a-synuclein accumulates as
neuronal insoluble aggregates in a mouse model of MPS-IIIA and
showed that this accumulation depletes synaptic a-synuclein,
contributing to neurodegeneration by a loss-of-function mecha-
nism.12 Nevertheless, the neuropathogenic relevance of amyloid
deposition itself and in particular its potential gain-of-toxic function
in the context of LSDs remains largely unexplored.
Here, we studied amyloidogenic protein aggregation in the brain of
mice with MPS-IIIA, one the most common and severe types of
neurodegenerative LSDs, and found that neuronal cell bodies provide
a major site for progressive deposition of multiple amyloid proteins
including a-synuclein, prion protein (PrP), Tau, and amyloid-b pro-
tein (Ab). Importantly, we demonstrated that preventing amyloid
aggregation by using a broad-spectrum inhibitor of amyloid self-
assembly protected against neurodegeneration in MSP-IIIA mice,
thus identifying a new attractive therapeutic strategy for MPS-IIIA
and likely for other LSDs.Molecular Therapy Vol. 28 No 4 April 2020 ª 2020 The Author(s). 1
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)
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Multiple Amyloid Proteins Progressively Accumulate into the
MPS-IIIA Mouse Brain
MPS-IIIA is caused by an inherited deﬁciency of sulfamidase, a
lysosomal hydrolase involved in the degradation of heparan-sulfate
glycosaminoglycan (GAG).13 Although in MPS-IIIA mice GAGs
begin to accumulate into the lysosomes postnatally, ALP becomes
defective only at 6 months of age, when severe neurological de-
fects, including neuroinﬂammation, synaptic dysfunction, and
cognitive deﬁcits also appeared and then worsened progressively
as the mice aged.12,14,15 Thioﬂavin-S and Congo red staining in
MPS-IIIA mouse brain and thioﬂavin-T ﬂuorescence assay in
MPS-IIIA brain homogenates revealed a massive amyloid protein
aggregation in different brain regions starting at 5–6 months of
age and increasing progressively with age (Figures 1A, 1B, and
S1). We have demonstrated previously that a-synuclein accumulates
in the perykaria of neurons of MPS-IIIA mice.12 To test whether
a-synuclein was a component of the observed amyloid deposits,
we performed immunohistochemistry (IHC) analysis with protein-
ase-K digestion. This analysis showed that a-synuclein inclusions
found in MPS-IIIA mouse brain were resistant to the digestion, a
key feature of amyloid deposits (Figures 1C and S2A). We tested
next whether other proteins also were present in the amyloid de-
posits by using antibodies against different known aggregation-
prone amyloidogenic proteins, including Tau, PrP, Ab, huntingtin,
and TAR DNA-binding protein (TDP-43).16 A strong proteinase
K-resistant immunoreactivity was found for Tau, PrP, and Ab in
several brain regions of the MPS-IIIA mice (Figures 1D, S2B, and
S2C). Confocal-microscopy analysis showed that brain inclusions
of these proteins were, for the most part, also thioﬂavin-S-positive,
supporting their amyloid nature (Figure S3). Co-labeling of thioﬂa-
vin-S with speciﬁc markers of glial and neuronal cells showed that a
major part of the thioﬂavin-S signal localized in the perikaryal re-
gion of neurons (Figures 1E and S4). Thioﬂavin-S ﬂuorescence
and amyloid protein immunoreactivity signals were also analyzed
in terms of subcellular localization and shape. Although a fraction
of the signal could be detected as characteristic axonal spheroids
or ﬁlamentous deposits, the majority was found as cell body inclu-
sions (Table S1). Thus, multiple amyloid proteins progressively de-
posit in the brain of MPS-IIIA mice mainly localizing in neuronal
cell bodies.Figure 1. Progressive Amyloidogenic Protein Deposition in MPS-IIIA Mouse Br
(A) Sagittal brain sections of WT and MPS-IIIA mice stained with thioflavin-S (FITC filter
termediate (5–6 months), and late (9–10 months). The cerebral cortex and ventral striatu
time point; the arrows indicate the perikaryal/perinuclear accumulation, whereas arro
emission 485 nm) was quantified in WT and MPS-IIIA brain homogenates (N = 5 for
mogenates of 1-month-old WT mice. Data are represented as means with SD. (C) a-sy
regions of WT and MPS-IIIA mice (9 months of age) without/with proteinase-K treatmen
Immunohistochemistry was performed after proteinase-K treatment on sagittal sections
using specific antibodies against PrP, Tau, or Ab. Enlarged images of MPS-IIIA brain sect
Immunofluorescence analysis on sagittal cortical brain sections of MPS-IIIA mice (late ti
the parietal cerebral cortex (layers I–V). Confocal images (63) show thioflavin-S co-loca
in the indicated region. Scale bars represent 1 mm (A), 12 mm (A, zoom images), 25 mm
(zoom images in C and D).The Molecular Tweezer CLR01 Efficiently Inhibits Amyloid
Protein Aggregation in the MPS-IIIA Mouse Brain
To address whether amyloid aggregation in MPS-IIIA mice was
relevant for neuropathogenesis, we treated mice with a broad-
spectrum inhibitor of amyloid protein oligomerization and aggrega-
tion, the “molecular tweezer” CLR01 (Figure 2A) and studied its
impact on neuropathology. Molecular tweezers act by a process-spe-
ciﬁc mechanism binding to lysine residues and disrupting molecular
interactions that are important for the abnormal self-assembly of
multiple amyloidogenic proteins.17,18 The lead molecular tweezer
CLR01 was selected out 10 ﬁrst-generation molecular tweezers de-
rivatives, based on its low toxicity and high efﬁcacy inhibiting
Ab-induced toxicity in cell culture. It was also evaluated for its
pharmacokinetic characteristics and safety in mice using both
acute and chronic administration.19 CLR01 was shown to be very
effective in protecting against neurodegeneration by inhibiting pro-
tein aggregation in mouse models of synucleinopathies, Alzheimer’s
disease (AD), and transthyretin amyloidosis.20–23 Importantly,
systemic administration of CLR01 is safe in mice and allows for
efﬁcient brain targeting due to the capability of CLR01 to cross
the blood-brain barrier.19 We treated the MPS-IIIA mice starting
at 4.5 months of age, before massive amyloid aggregation takes
place, with daily sub-cutaneous injection of CLR01 over a period
of 4.5 months. At the end of treatment, 9-month-old MPS-IIIA
mice showed a strong reduction in thioﬂavin-S and thioﬂavin-T
reactivity (Figures 2B and 2C) and, correspondingly, a striking
decline in the build-up of speciﬁc components of amyloid deposits
(Figure 2D).
CLR01 Treatment Relieves Autophagy-Lysosomal Dysfunction
in the MPS-IIIA Mouse Brain
Lysosomal enlargement and autophagy dysfunction are associated to
neurodegeneration in several LSDs, including the MPS-IIIA.2,4
Consistent with the large expansion of the lysosomal compartment,
a pathological hallmark of LSDs, anti-LAMP1 IHC showed an
increased signal in MPS-IIIA mouse brain compared to age-matched
wild-type (WT) mice (Figure 3A). Electron microscopy (EM) analysis
revealed that this increased LAMP1 immunoreactivity reﬂected
enlargement of the average lysosome size associated with an increase
in the number of abnormal-sized lysosomes (>800 nm) at the expense
of normal-sized lysosomes (400 nm) (Figure 3B). CLR01 treatmentain
; excitation 488 nm, emission 520 nm) at three time points: early (2–3 months), in-
m areas displaying a typical staining pattern are highlighted on the right, for the late
wheads indicate axonal staining. (B) Thioflavin-T fluorescence (excitation 450 nm,
each indicated time point); data were normalized to the fluorescence of brain ho-
nuclein immunohistochemistry on sagittal sections derived from the indicated brain
t. Enlarged images of the MPS-IIIA stained sections are shown in the right panel. (D)
derived from the indicated brain regions of WT and MPS-IIIA mice (9 months of age)
ions are shown in the right panels. Scale bars represent 25 mmand 10 mm (zoom). (E)
me point). Epi-fluorescence images (10) show thioflavin-S co-stained with DAPI in
lization with neuronal (NeuN), astroglial (GFAP, S100b), and microglial (Iba1) markers
(E, confocal images), 50 mm (E, epi-fluorescent images), 50 mm (C and D), and 5 mm
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Figure 2. CLR01 Treatment Inhibits Amyloid Deposition in the Brain of MPS-IIIA Mice
(A) Chemical structure of CLR01 showing the aromatic backbone and two phosphate groups, which confer the specificity for binding to positively charged amino acid side
chains. (B) CLR01 was injected daily at 1 mg/Kg subcutaneously to 4.5-month-old WT and MPS-IIIA mice over a period of 4.5 months. As a control, WT and MPS-IIIA mice
were treated with saline. Thioflavin-S staining was performed at the end of treatment (9 months of age) on sagittal sections derived from the indicated brain regions of the four
experimental groups of mice (WT saline-injected, WT CLR01-injected, MPS-IIIA-saline injected, and MPS-IIIA CLR01-injected) showed a reduction of amyloid deposition in
the brain of CLR01 treated MPS-IIIA mice. (C) Thioflavin-T fluorescence (excitation 450 nm, emission 485 nm) was quantified in the brain homogenates derived from the four
experimental groups of mice (N = 5 for each indicated time point); data were normalized to the fluorescence of brain homogenates of 1-month-old WT mice. ***p < 0.001
versus WT; ###p < 0.001 versus MPS-IIIA + saline, one-way ANOVA with Bonferroni’s multiple comparison test. Data are represented as means ± SEM. (D) Immunohis-
tochemistry with proteinase-K treatment was performed at 9 months of age on sagittal cortical sections of mice belonging to the four experimental groups using antibodies
against specific amyloid proteins (a-synuclein and tau are shown). A strong reduction in proteinase K-resistant aggregates was found in MPS-IIIA brain treated with CLR01
compared to MPS-IIIA brain treated with saline. Scale bars represent 50 mm (B) and 12.5 mm (D).
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Storage Disease, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.02.005markedly reduced the enlargement of the lysosomal compartment in
the MPS-IIIA mouse brain (both the average size and the number of
abnormal-sized lysosomes were reduced) but did not modify it inWT
mice (Figures 3A and 3B).
We then analyzed the autophagy ﬂux in the MPS-IIIA mouse brain
following CLR01 treatment. In healthy neurons, autophagosome
vesicles (AVs) are continuously generated in the axons and efﬁ-
ciently cleared upon fusion with lysosomes in the cell body and,
therefore, are rarely found in neurites or cell bodies unless lyso-
some-dependent AV clearance is disrupted.24–26 Immunoﬂuores-
cence analysis of the AV marker LC3 showed a striking increase
in the overall number of LC3-positive puncta in MPS-IIIA brain
compared to WT mouse brain (Figure 3C). Interestingly, the major-
ity of LC3-puntca were not within the soma of cells (Figure 3C).
This result was consistent with a block of the autophagic ﬂux, as
shown in previous reports.12,27 CLR01 treatment signiﬁcantly
decreased the overall number of LC3-positive puncta in the MPS-
IIIA brain, indicating that lysosomal-mediated clearance of
autophagosomes was efﬁciently restored by inhibiting amyloid
deposition (Figure 3C). Importantly, no signiﬁcant change in LC3
staining was observed in CLR01-treated WT mice (Figure 3C).
We also monitored the levels of NBR1, an autophagy cargo recep-
tor.28 Western-blot anti-NBR1 showed an accumulation of NBR1
protein in the brain of MPS-IIIA mice that was signiﬁcantly reduced
upon CLR01 treatment (Figure 3D), thus further supporting the
conclusion that inhibition of amyloid deposition by CLR01 reacti-
vated the autophagic ﬂux in MPS-IIIA brain.4 Molecular Therapy Vol. 28 No 4 April 2020CLR01 Treatment Ameliorates Neurodegenerative Signs in
MPS-IIIA Mice
Next, we tested whether CLR01-mediated restoration of ALP inMPS-
IIIA brain was associated with a neuroprotective effect. Neuro-
inﬂammation is one of the most prominent signs of neuropathology
in MPS-IIIA.29,30 We found that CLR01 treatment strongly reduced
the neuro-inﬂammation in the MPS-IIIA mice while it had no effect
on WT mice (Figure 4A). EM analysis of cortical synapses showed
that CLR01 treatment also rescued loss of synaptic vesicles (Fig-
ure 4B), another pathological feature that has been reported in
MPS-IIIA mouse brain.12,29 Recent data demonstrated that MPS-
IIIA mice develop a strong age-dependent memory impairment in
the contextual fear-conditioning test.31 Indeed, untreated 9-month-
old MPS-IIIA mice showed a severe memory deﬁcit compared to
WT mice, which, remarkably, was fully rescued by CLR01 treatment
(Figure 4C). Taken together, our data showed that CLR01-mediated
inhibition of amyloid formation in MPS-IIIA by CRL01 mice restores
ALP function and reduces neuropathological signs signiﬁcantly, thus
indicating that amyloid deposition contributes to the neurodegener-
ative processes in a relevant model of neurodegenerative LSDs. To
support these ﬁndings, we also tested whether CLR01 also could
improve neuropathology when administered at a late stage of disease
progression, when amyloid deposition had already occurred. To this
aim, we treated MPS-IIIA at 7 months of age continuously until
11 months of age. This treatment regimen did not affect the buildup
of amyloid inclusions and did not improve signiﬁcantly neither the
ALP functionality nor neurodegenerative signs (Figure S5). There-
fore, CLR01 was effective in preventing amyloid aggregation but
Figure 3. CLR01 Treatment Reduces Lysosomal Enlargement and Restores Autophagy Flux in the Brain of MPS-IIIA Mice
(A) Immunohistochemistry using an anti-Lamp1 antibody was performed on sagittal brain sections derived from the four experimental groups of mice at 9 months of age.
Images from cerebral cortex are shown. Lamp1 immunoreactivity was quantified in 10 different fields from cortical regions for each group. Three mice were analyzed for each
experimental group. ***p < 0.001 versus WT; ###p < 0.001 versus MPS-IIIA + saline, one-way ANOVA with Bonferroni’s multiple comparison test. Data are represented as
means ± SEM. (B) Transmission electron microscopy (TEM) analysis was used to quantify the number and size of lysosomal-like structures (black arrows) in the four
experimental groups of mice at 9 months of age. For size measurement, at least 150 lysosomes from the cortical regions for each group were analyzed. For number
measurement, ~20 fields from the cortical regions for each group were analyzed. Three mice were analyzed per group. Representative TEM images are shown on the left
panel. ***p < 0.001 versus WT; ##p < 0.01, ###p < 0.001 versus MPS-IIIA + saline, respectively, one-way ANOVA with Bonferroni’s multiple comparison test. Data are
represented as means ± SEM. (C) Immunofluorescence using an anti-LC3 antibody was performed on indicated sagittal brain sections from the four experimental groups of
mice at 9 months of age. Large LC3-positive puncta (>3 mm2) were considered as area containing several accumulating AVs. LC3 puncta ranging from 0.5 to 3 mm2 were
considered as area containing normal sized AVs. The number of LC3-positive puncta was quantified in 15 different fields from the cortical regions for each group.
Three mice were analyzed per group. ***p < 0.001 versus WT; ###p < 0.001 versus MPS-IIIA + saline; ##p < 0.01 versus MPS-IIIA; #p < 0.05 versus MPS-IIIA, one-way
(legend continued on next page)
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further support the functional relationship between amyloid
accumulation, ALP dysfunction, and neurodegenerative processes
in MPS-IIIA.
DISCUSSION
Targeting secondary pathogenic processes may represent a valuable
option for the treatment of LSDs that is alternative to the correction
of the primary genetic defect.32 Finding effective druggable thera-
peutic targets may also open the possibility of improving existing
therapeutic protocols and, in principle, may be applied to several
LSDs.33
Our data demonstrate that multiple amyloid proteins massively accu-
mulate mainly in neuronal cell bodies of a mouse model of MPS-IIIA,
a severe neurodegenerative LSD, and that inhibiting amyloid deposi-
tion by CLR01 relieves ALP dysfunction and ameliorates neurological
signs in MPS-IIIA mice. Importantly, CLR01 effect on autophagy
must have been mediated by the inhibition of amyloid deposition
because no appreciable change in the lysosomal-autophagic axis
was observed in WT mice upon CLR01 treatment, thus ruling out a
direct effect of CLR01 on ALP. Therefore, our data pointed out on
a neurotoxic effect of amyloid deposition in MPS-IIIA that is associ-
ated to the impairment of ALP, thus identifying amyloid aggregation
as a new therapeutic target for MPS-IIIA. How amyloid protein depo-
sition affects ALP remains to be elucidated. Mechanisms underlying
such effects may involve the negative impact of amyloids on lyso-
somal trafﬁcking and signaling pathways, which have been shown
to be critical for autophagy.26,34 The ﬁnding that LC3 puncta accumu-
late out of cell bodies (likely in neurites) suggests a mechanism by
which amyloid deposition impairs autophagosome maturation. A
point that also needs to be clariﬁed is what initiates amyloid protein
deposition. One possibility is that primary lysosomal storage induces
amyloid protein deposition. Supporting this hypothesis, it has been
reported that GAGs provide a scaffold promoting amyloid aggrega-
tion.35,36 Moreover, the autophagy block may, in turns, boost amyloid
build-up, thus generating a vicious cycle that can be interrupted by
CLR01 treatment.
In conclusion, our data showed that the brain deposition of multiple
amyloidogenic proteins plays a key role in the onset of neuropa-
thology in a severe form of neurodegenerative LSDs and that the
amyloid self-assembly inhibitor CLR01 can efﬁciently protect against
neurological lesions. Importantly, our data indicate that the neuro-
protective effect of CLR01 is associated with the restoration of ALP.
These ﬁndings provide new insights into the processes triggering neu-
rodegeneration in LSDs and identify amyloid deposition counteract-
ing as a new attractive therapeutic strategy forMPS-IIIA and likely for
other LSDs.ANOVA with Bonferroni’s multiple comparison test. Data are represented as means ± S
brain homogenates derived from the four experimental mouse groups at 9 months of ag
WT; #p < 0.05 versus MPS-IIIA, one-way ANOVA with Bonferroni’s multiple comparison
and 0.4 mm (B).
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Animals
MPS-IIIA mice (homozygous mutant Sgsh/)15, together with
respective control littermate WT (+/+), were utilized. All mice were
C57BL/6 congenic. Animal studies were conducted in accordance
with the guidelines of the Animal Care andUse Committee of TIGEM
in Naples and authorized by the Italian Ministry of Health.CLR01 Injection
CLR01 was synthesized in the lab of Thomas Schrader and Frank-
Gerrit Klärner, both at the University of Duisburg-Essen (UDE) in
Germany.37 The corresponding composition of matter and methods
of use intellectual property (IP) are held jointly by UCLA (Gal Bitan)
and UDE (Thomas Schrader and Frank-Gerrit Klärner) in Interna-
tional Patent No. PCT/US2010/026419, USA patent No. 8,791,092,
European patent No. EP2403859 A2 (Massachusetts Institute of
Technology is a minor partner), and International Patent Application
No. PCT/US2019/039943 (Ulm University, Germany is also a part-
ner). The method of use applied to lysosomal storage diseases that
was discovered by Alessandro Fraldi at the Telethon Institute of Ge-
netics and Medicine (TIGEM), Italy, is protected by International
Patent Application No. PCT/US2019/029222, which is held jointly
by TIGEM and UCLA. CLR01 powder was dissolved in phosphate-
buffered saline (PBS pH 7.4) at concentration of 0.7 mg/mL. Each
day the MPS-IIIA and WT mice were weighed and a volume of the
CLR01 solution corresponding to 1 mg/kg/day (approximately 50–
60 mL of solution per mouse) was subcutaneously injected. Control
mice, both MPS-IIIA and WT, were treated similarly with PBS only.Brain Collection
After euthanizing, mouse brains were collected from each experi-
mental group and perfused with PBS to clear blood from the tissue.
The brains were divided into the two hemispheres: one was frozen
in dry ice and used for biochemical analysis and the other was ﬁxed
in 4% (w/v) paraformaldehyde in PBS and embedded in optimal cut-
ting temperature compound (OCT compound) or parafﬁn.Brain Homogenization and Protein Extraction
Brain hemispheres were ruptured in 6 volumes of milli-Q water con-
taining Protease Inhibitor Cocktail Set I (Calbiochem) by using the
TissueLyser LT (QIAGEN). Lysates were subjected to ﬁve freeze-
thaw cycles. Water homogenates were used for thioﬂavin T assays.
Brain homogenates were also used for proteins extraction performed
by radioimmunoprecipitation assay (RIPA) buffer containing 1%
Triton X-100 and Protease Inhibitor Cocktail Set I (Calbiochem).
Samples were subjected to a centrifugation at 10,000 rpm for
10 min, and the supernatants were collected as protein-enrichedEM. (D) Western-blot analysis of the autophagy markers NBR1 was performed in the
e. NBR1 signal was quantified and normalized to GAPDH signal. **p < 0.01 versus
test. Data are represented as means ± SEM. Scale bars represent 25 mm (A and C)
Figure 4. CLR01 Treatment Ameliorates Neuropathological Signs in MPS-IIIA Mice
(A) Immunohistochemistry with anti-GFAP and anti-Iba-1 antibodies was performed on sagittal both cortical and striatal brain sections derived frommice belonging to the four
experimental groups at 9 months of age. Images show a reduction of both inflammatory markers in MPS-IIIA mice upon CLR01 treatment. GFAP and Iba1 immunoreactivity
were quantified in 10–15different fields. Threemice for each experimental groupwere analyzed. *p < 0.05 versusWT+ saline; ***p <0.001 versusWT+saline; #p<0.05, ##p<
0.01, ###p < 0.001 versus MPS-IIIA + saline; one-way ANOVA with Bonferroni’s multiple comparison test. Data are represented as means ± SEM. (B) TEM analysis of
synaptic-vesicle number was performed in the cerebral cortex of mice belonging to the four experimental groups at 9 months of age. The graphic representation shows the
synaptic vesicles/synaptic cleft length ratio for at least 50 synapses derived from3mice for each experimental group. The arrows indicate the synaptic cleft. ***p < 0.001 versus
WT + saline; ###p < 0.001 versusMPS-IIIA + saline, one-way ANOVA analysis with Bonferroni’s multiple comparison test. (C)Memory function was tested inmice at 9months
of age using the contextual fear-conditioning task. Three different cohorts of injected animals were used. Graphical representation of contextual fear-conditioning results
(freezing time during training and test) show that memory deficits in control MPS-IIIA mice (reduced freezing time) were rescued by CLR01 treatment. 7–11male mice in each
groupwere tested. Repeated-measures ANOVA:Genotype F1,29 = 23.046; p < 0.0001; Treatment F1,29 = 7.862; p = 0.0089; Freezing F1,29 = 241.926; p < 0.0001; Freezing
Genotype F1,29 = 42.580; p < 0.0001; Freezing  Treatment F1,29 = 14.086; p = 0.0008. *p < 0.05 versus WT; #p < 0.05 versus MPS-IIIA, Duncan post hoc test. WT saline
(n = 7), WT + CLR01 (n = 7), MPS-IIIA saline (n = 11), MPS-IIIA + CLR01 (n = 8). Data are represented as means ± SEM. Scale bars represent 25 mm (A) and 0.2 mm (B).
www.moleculartherapy.org
Please cite this article in press as: Monaco et al., The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal
Storage Disease, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.02.005solutions. Protein samples were loaded onto a 12% SDS-PAGE in or-
der to analyze NBR1 expression by western blotting.
Thioflavin T Assay
The brain homogenates were sonicated and quantiﬁed for protein
content by Bradford assay. 50 mg of homogenate were incubated for
5 min at room temperature with thioﬂavin T (ab120751, Abcam) pre-
pared at 20 mM in water. Fluorescence emission at 485 nm (excitation
at 450 nm) then was measured at 37C. The ﬂuorescence values werenormalized by subtracting the ﬂuorescence coming from brain ho-
mogenates derived from 1-month-old WT mice.
Antibodies
Polyclonal rabbit antibody anti-a-synuclein (#128102, Synaptic Sys-
tem, Goettingen, Germany, IHC, IF: 1:300), polyclonal goat antibody
anti-PrP (ab6664, Abcam, Cambridge, UK, IHC, IF: 1:400), mono-
clonal mouse antibody anti-Tau (Tau 46) (#4019, Cell Signaling
Technology, Danvers, USA, IHC, IF: 1:400), monoclonal rabbitMolecular Therapy Vol. 28 No 4 April 2020 7
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IHC, IF: 1:200), polyclonal rabbit antibody anti-TDP-43 (#10782-
2AP, Proteintech, Chicago, USA, IHC: 1:200),monoclonal rabbit anti-
body anti-huntingtin (ab109115, Abcam, IHC: 1:100), polyclonal rab-
bit antibody anti-glial ﬁbrillary acidic protein (GFAP) (Z0334, DAKO
Agilent, Santa Clara, USA, IF, IHC: 1:400), polyclonal rabbit antibody
anti-IBA 1 (019-19741,Wako, USA, IHC, IF: 1:200), polyclonal rabbit
antibody anti-LC3 (PM036, MBL, Woburn, USA, IF: 1:1,000), mono-
clonal rat antibody anti-Lamp1 (SC-19992, Santa Cruz, Dallas, USA,
IF: 1:50), polyclonal rabbit antibody anti-Lamp1 (ab24170, Abcam,
IHC: 1:200), polyclonal rabbit antibody anti-S-100b (ab52642, abcam,
IF: 1:200), monoclonalmouse antibody anti-NBR1 (H00004077-M01,
Abnova, Taiwan, WB: 1:1,000); monoclonal mouse antibody anti-
NeuN (MAB377, Millipore, IF: 1:400), and monoclonal mouse
antibody anti-Olig-2 (MABN50,Millipore, IF: 1:200). Alexa Fluor sec-
ondary antibodies used in immunoﬂuorescence experiments were
purchased from Molecular Probe (Invitrogen).
Proteinase K Treatment
We used a standard protocol as in Roberts et al.38 Brieﬂy, after rehy-
dration, 6-mm thick parafﬁn sections were treated with 3% H2O2 for
1 h to quench the endogenous peroxidases. Proteinase K (Euroclone)
was added onto the parafﬁn sections at a concentration of 50 mg/mL
for 2 min at 37C. If indicated, unmasking was eventually performed
by incubating sections for 10 min in a citrate buffer, pH 6, in a micro-
wave oven. After blocking, sections were incubated with the speciﬁc
antibodies.
Immunofluorescence and Immunohistochemistry
Medial sagittal 10 mm sections of frozen brain tissue were cut using a
cryostat, permeabilized in PBS containing 0.05% Saponin, and 10%
fetal bovine serum), and incubated with the appropriate primary anti-
body overnight at +4C followed by 1 h at room temperature with the
secondary antibody. Stained sections were mounted with Vectashield
(Vector Laboratories, CA, USA). Sections were analyzed using a Leica
upright DM5500microscope or a confocal Zeiss LSM 700microscope
using either 63 or 40 objectives.
The percentage of colocalization was evaluated on confocal images by
using the tool “Colocalization Test” of the ImageJ software.
Analysis of LC3 dots was performed by using the tool “analyze parti-
cles” of the ImageJ software. Counting of dots was performed using a
circularity of 0.5–1. Because AV size normally ranges from 0.2 to
2–3 mm,2,39 dots smaller than 0.2 mm2 were not considered in the
analysis. The LC3 dots were divided in two different populations
based on their size; dots ranging from 0.2 to 3 mm2 were considered
normal and dots greater than 3 mm2 were considered large. Moreover,
the large LC3 dots were further divided in three different classes from
3 mm2 to 5 mm2, 5 mm2 to 10 mm2, and >10 mm2.
For parafﬁn embedding, mouse brains were ﬁxed in 4% paraformal-
dehyde (PFA) overnight at 4C, then dehydrated in a graded series of
ethanol, cleared with xylene, and inﬁltrated with parafﬁn. Parafﬁn-8 Molecular Therapy Vol. 28 No 4 April 2020embedded blocks were cut on a microtome into 6-mm sagittal sec-
tions. All immunohistochemistry staining was performed using the
Vectastain Elite ABC-HRP Kit (PK6200 Vector Laboratories). Visu-
alization was performed using 3,3-diaminobenzidine tetrahydro-
chloride (DAB Vector Laboratories). Bright-ﬁeld images were
observed using an upright Leica DM5500 microscope. Quantitation
of the stained area in immunohistochemistry experiments was per-
formed by using the tool “measure” of ImageJ after the conversion
of images to 8-bit format and the adjustment of the threshold.
Thioflavin-S Staining
Cryo-sections (10 mm) were incubated in 0.01% (w/v) thioﬂavin-S
(T1892 SIGMA) for 10 min. Slides were washed in PBS 3 times and
mounted using Vectashield mounting medium with 40,6-diami-
dino-2-phenylindole (DAPI; Vector Laboratories, CA, USA). Positive
staining was observed using an upright Leica DM5500 microscope
with the ﬂuorescein isothiocyanate (FITC) ﬁlter. For the scan of the
entire sections, the images were acquired by Scan-Scope slide scanner
(Leica scn400).
Congo Red Staining
Parafﬁn sagittal brain sections (6 mm) were deparafﬁnized, hydrated,
and stained with Mayer’s hematoxylin solution for 10 min. After a
rinse in tap water for 5 min, the sections were placed in alkaline so-
dium chloride solution (Sigma-Aldrich, HT60) for 20 min and then
stained for 20 min in a Congo red solution (Sigma-Aldrich, HT60).
The sections were rinsed 3 times in absolute ethanol, cleared in
xylene, and mounted. The images were acquired using an upright
Leica DM5500 microscope.
Electron Microscopy
Cortex regions were ﬁxed in 1% glutaraldehyde and 4% PFA in
200mMHEPES, pH 7.3, for 10min at 37C, post-ﬁxed in 1% osmium
tetroxide, dehydrated, and embedded in resin. Ultra-thin sections
were cut on a LEICA EM UC7 ultramicrotome and the morphology
of cellular and subcellular structures was analyzed by the TIGEM EM
core. Lysosome size and number were evaluated using the software
iTEM (Olympus). “Lysosomes” were identiﬁed by morphometric
analysis as a wide spectrum of lysosome-like structures that includes
bona ﬁde lysosomes, autolysosomes, multi-vesicular bodies, and vac-
uoles with stored undigested material.
Contextual Fear Conditioning Test
The contextual fear conditioning task allows to evaluate the mouse
ability to learn and remember a Pavlovian association between a
mild food-shock and a speciﬁc context. The test was carried out in
a behavioral testing room maintained under constant light, tempera-
ture, and humidity. The mice were tested during daylight hours
(between 9 am and 6 pm). Before testing, animals were habituated
to the testing room for at least 30 min.
Each mouse was trained in a conditioning chamber (30 cm 
24 cm 21 cm; Ugo Basile) that had a removable grid ﬂoor and waste
pan. The grid ﬂoor contained 36 stainless steel rods (3-mm diameter)
www.moleculartherapy.org
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ﬂoor contacted a circuit board through which scrambled shock was
delivered. The shock intensity was 0.5 mA with a duration of 2 s
and it was presented three times and was associated with a context.
24 h after training, mice were tested without foot-shock but with
the same context. Freezing behavior was deﬁned as a complete lack
of movement, except for respiration, and scored using a video-
tracking system (ANY-MAZE, Stoelting, USA).Statistical Analysis
Data of behavioral tests were expressed as mean ± SEM. Two-
way ANOVA for repeated-measures with the factor group as
independent factor and trials or test phase as repeated-measures
was performed to assess signiﬁcance among multiple experimental
groups and at different time points, followed by Duncan post hoc
test when appropriate. A p < 0.05 was considered as statistically
signiﬁcant.
For all the other experiments, the data were expressed as mean ±
SEM. The signiﬁcance of difference among the experimental groups
were calculated by one-way ANOVA followed by Bonferroni post
hoc test. A p < 0.05 was considered as statistically signiﬁcant.SUPPLEMENTAL INFORMATION
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